Biospecimen Exchange for Neurological Disorders (BioSEND)

神经系统疾病生物样本交换 (BioSEND)

• 批准号: 10289967
• 负责人: TATIANA M. FOROUD
• 金额: $ 150万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10289967
• 关键词: Aliquot; Award; Basic Science; Biological Markers; Biological Specimen Banks; Blinded; Catalogs; Cerebrospinal Fluid; Chronic Fatigue Syndrome; Clinical Data; Clinical Research; Communities; Custom; DNA; Data; Data Analyses; Data Coordinating Center; Dementia with Lewy Bodies; Disease; Ensure; Epilepsy; Faculty; Frontotemporal Dementia; Funding; Genetic Markers; Growth; Human; Huntington Disease; Indiana; Infrastructure; Institutes; Institution; Laboratories; Leadership; Lewy Body Dementia; Link; Medical Research; Mission; Names; National Institute of Neurological Disorders and Stroke; Parkinson Disease; Peripheral Blood Mononuclear Cell; Plasma; Protocols documentation; Quality Control; RNA; Research; Research Personnel; Research Subjects; Resources; Saliva; Sampling; Sampling Studies; Science; Secure; Site; Specimen; Spinocerebellar Ataxias; Time; Training; Translational Research; Traumatic Brain Injury; Universities; Urine; Work; base; biobank; data management; data repository; data sharing; experience; innovation; material transfer agreement; nervous system disorder; quality assurance; repository; response; success; vascular cognitive impairment and dementia; web site

PROJECT SUMMARY/ABSTRACT We have prepared this application in response to RFA-NS-20-031, which invites applicants to serve as the NINDS Human Biospecimen and Data Repository in Neurological Disorders. The BioSpecimen Exchange for Neurological Disorders (BioSEND) was awarded to Indiana University on September 30, 2015. This application proposes to renew and retain BioSEND at Indiana University and expand the impact and success of BioSEND through additional innovations and improvements. With the transfer of the NINDS-funded biorepository to Indiana University, BioSEND dramatically expanded the number of disorders for which samples are banked. The scope and scale of banking has also dramatically increased with the establishment of BioSEND at Indiana University. The value of the biospecimens banked at BioSEND is demonstrated by the substantial growth in the requests for these samples by researchers. Over the past five years, BioSEND has made 93 distributions to 42 investigators at more than 30 institutions. Indiana University has developed a strong biorepository team consisting of faculty with critical scientific and leadership experience and staff with essential expertise in biobanking, clinical research coordination, and data management. Over the past five years, we have developed a strong infrastructure and implemented a customer- focused approach that employs innovative solutions to both specimen banking and distribution. Based on our success in establishing a widely used biospecimen repository, we plan further improvements and expansion of BioSEND to meet the NINDS mission to increase biobanking to support basic, translational and clinical research in neurological disorders. We propose to pursue the following specific aims for the next five years: Aim 1: Provide leadership to BioSEND Aim 2: Provide study management expertise Aim 3: Provide scientific and laboratory expertise Aim 4: Distribute samples to approved researchers Aim 5: Develop custom solutions to link clinical data with biospecimens

项目摘要/摘要 我们是应RFA-NS-20-031号文件的要求准备这份申请的，该文件邀请申请者担任 NINDS神经疾病中的人类生物样本和数据库。生物胺交换剂 2015年9月30日，印第安纳大学被授予神经疾病奖(BioSEND)。此应用程序 建议在印第安纳大学更新和保留BioSEND，并扩大BioSEND的影响和成功 通过更多的创新和改进。 随着NINDS资助的生物信息库转移到印第安纳大学，BioSEND的规模急剧扩大 为其存储样本的疾病数量。银行业的范围和规模也急剧增加。 随着印第安纳大学BioSEND的建立，这一数字有所增加。生物质学家的价值被储存在 研究人员对这些样本的要求大幅增加，证明了BioSEND的存在。超过了 在过去的五年里，BioSEND已经向30多个机构的42名调查人员分发了93份材料。 印第安纳大学开发了一支强大的生物信息库团队，由具有关键科学和技术的教师组成 在生物库、临床研究协调和数据方面具有基本专业知识的领导经验和员工 管理层。在过去的五年里，我们开发了强大的基础设施，并实施了客户- 专注的方法，采用创新的解决方案，以样本银行和分销。基于我们的 成功建立一个广泛使用的生物谱系资料库，我们计划进一步改善和扩展 BioSEND将满足NINDS的使命，增加生物库，以支持基础、翻译和临床研究 在神经性疾病方面。我们建议在未来五年实现以下具体目标： 目标1：为BioSEND提供领导力 目标2：提供研究管理专业知识 目标3：提供科学和实验室方面的专门知识 目标4：将样本分发给经批准的研究人员 目标5：开发将临床数据与生物样品联系起来的定制解决方案